Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsOPHTHALMICGeneric

LUMIGAN

BIMATOPROST

Standard Dose
0.03% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview LUMIGAN is listed in Drugs@FDA under application 021275 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient BIMATOPROST Form and strength SOLUTION/DROPS;OPHTHALMIC - 0.03% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ABBVIE Submission history Latest submission status date: 2022-03-08 00:00:00.

Structured Monograph

Clinical summary

Approval overview LUMIGAN is listed in Drugs@FDA under application 021275 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient BIMATOPROST Form and strength SOLUTION/DROPS;OPHTHALMIC - 0.03% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ABBVIE Submission history Latest submission status date: 2022-03-08 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
LUMIGAN (BIMATOPROST) | Drug Monograph | MedicHelpline